Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-525 in B-Cell Malignancies
NCT05618028Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2023
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 1, open-label trial of ABBV-525 in B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), chronic lymphocytic leukemia (CLL) and 1 more (3 arms), sponsored by AbbVie Inc. Primary endpoints: Adverse Events at 64 months, Dose-Limiting Toxicities at 28 days and 7 more. Started Apr 2023; status: active, not recruiting.
02
Drugs
ABBV-525
03
Conditions
B-cell malignancydiffuse large B-cell lymphoma (DLBCL)chronic lymphocytic leukemia (CLL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05618028.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618028.